Evidence map›Paper›PMID 37711730›Full record

ArticleDrugs in context2023

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region.

Alejandro Bimbo Diaz, Jeremy Chow, Fan Kee Hoo, Kok Wei Koh, Gary Chin Keong Lee, Wee Siong Teo, Narayanaswamy Venketasubramanian, Chun-Chieh Wang, Radhika Mehta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drugs in context, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alejandro Bimbo DiazUniversity of Santo Tomas Hospital, Manila, Philippines.
Jeremy ChowAsian Heart & Vascular Centre, Singapore, Singapore.
Fan Kee HooUniversity Putra Malaysia, Serdang, Malaysia.
Kok Wei KohSubang Jaya Medical Centre, Subang Jaya, Malaysia.
Gary Chin Keong LeeThomson Hospital Kota Damansara, Petaling Jaya, Malaysia.
Wee Siong TeoMount Elizabeth Medical Centre, Singapore, Singapore.
Narayanaswamy VenketasubramanianRaffles Hospital, Singapore, Singapore.
Chun-Chieh WangChang Gung Memorial Hospital, Linkou and Chang Gung University, Taoyuan, Taiwan.
Radhika MehtaA. Menarini Asia-Pacific Pte Ltd, Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Edoxaban, a once-daily, direct-acting oral anticoagulant, is approved to prevent stroke or systemic embolism in non-valvular atrial fibrillation (NVAF) and treat venous thromboembolism. The clinical benefit of edoxaban for stroke prevention in Asian patients with NVAF has been demonstrated in clinical and real-world studies. We share early clinical experiences with once-daily edoxaban and discuss its evidence-based use in patients with NVAF in Southeast Asia through several cases of patients at high risk, including frail patients, elderly patients with multiple comorbidities and patients with increased bleeding risk. These cases demonstrate the effectiveness and safety of once-daily edoxaban in patients with NVAF in Southeast Asia.

Indexed as

atrial fibrillationedoxabanSoutheast Asiastroke

Identifiers

PMID37711730
PMCPMC10499367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.